Press coverage about Veracyte (NASDAQ:VCYT) has been trending positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a coverage optimism score of 0.28 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.7633132699206 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

Veracyte (VCYT) traded up $0.05 during midday trading on Friday, hitting $5.98. The stock had a trading volume of 121,011 shares, compared to its average volume of 107,211. The company has a market cap of $205.06, a PE ratio of -6.57 and a beta of 1.61. Veracyte has a 12 month low of $5.23 and a 12 month high of $9.80. The company has a quick ratio of 4.86, a current ratio of 4.49 and a debt-to-equity ratio of 0.68.

VCYT has been the topic of a number of analyst reports. BTIG Research set a $13.00 price objective on shares of Veracyte and gave the stock a “buy” rating in a report on Monday, November 20th. Zacks Investment Research raised shares of Veracyte from a “sell” rating to a “hold” rating in a report on Friday, November 10th. Leerink Swann cut their price objective on shares of Veracyte from $12.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. Piper Jaffray Companies downgraded shares of Veracyte from an “overweight” rating to a “neutral” rating in a report on Tuesday, November 7th. Finally, ValuEngine downgraded shares of Veracyte from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. Veracyte presently has an average rating of “Hold” and a consensus price target of $10.78.

COPYRIGHT VIOLATION WARNING: “Veracyte (VCYT) Earns Media Sentiment Score of 0.28” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at

About Veracyte

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with's FREE daily email newsletter.